GlaxoSmithKline has extended its offer to acquire all of the outstanding shares of Human Genome Sciences for 1,300 cents per share until 17:00 on July 20th.
GSK's tender offer will expire after 16 July, the deadline set by HGS for submission of definitive acquisition proposals, after which GSK will consider all available options regarding its offer, but said it can make no assurance that the tender offer will be further extended.
The company reitered that it "remains willing to meet and review its offer with HGS at any time".
MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
The offer represents a premium of 81% to HGS's closing share price of $7.17 on April 18th , the last trading day before HGS publicly disclosed GSK's private offer.
"Given its near 20-year relationship with HGS and ownership of 50% of Benlysta as well as the vast majority of the economics associated with albiglutide and darapladib, GSK continues to believe it is uniquely positioned to deliver on the opportunity of the proposed combination," GSK commented.
GSK's share price fell 0.69% to 1,436p by 13:10.
NR
-
Reeves urged to axe stamp duty from UK shares held in an ISAChancellor Rachel Reeves is reportedly considering axing stamp duty from UK shares held in stocks and shares ISAs. What could it mean for your portfolio?
-
Family investment companies explained: how the ultra wealthy shield their money from the taxmanWealthy families are increasingly turning to family investment companies to keep more of their money away from HMRC – but what are these arrangements and how do they work?
